243 related articles for article (PubMed ID: 18393831)
21. Gene therapy with poxvirus vectors.
Moroziewicz D; Kaufman HL
Curr Opin Mol Ther; 2005 Aug; 7(4):317-25. PubMed ID: 16121697
[TBL] [Abstract][Full Text] [Related]
22. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
23. Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model.
Offerman K; Deffur A; Carulei O; Wilkinson R; Douglass N; Williamson AL
BMC Genomics; 2015 Jul; 16(1):510. PubMed ID: 26153454
[TBL] [Abstract][Full Text] [Related]
24. A chemically defined production process for highly attenuated poxviruses.
Jordan I; Northoff S; Thiele M; Hartmann S; Horn D; Höwing K; Bernhardt H; Oehmke S; von Horsten H; Rebeski D; Hinrichsen L; Zelnik V; Mueller W; Sandig V
Biologicals; 2011 Jan; 39(1):50-8. PubMed ID: 21237672
[TBL] [Abstract][Full Text] [Related]
25. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice.
Gómez CE; Nájera JL; Domingo-Gil E; Ochoa-Callejero L; González-Aseguinolaza G; Esteban M
J Gen Virol; 2007 Sep; 88(Pt 9):2473-2478. PubMed ID: 17698656
[TBL] [Abstract][Full Text] [Related]
26. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
27. The uses of poxviruses as vectors.
Vanderplasschen A; Pastoret PP
Curr Gene Ther; 2003 Dec; 3(6):583-95. PubMed ID: 14683453
[TBL] [Abstract][Full Text] [Related]
28. Poxvirus vectors: cytoplasmic expression of transferred genes.
Moss B
Curr Opin Genet Dev; 1993 Feb; 3(1):86-90. PubMed ID: 8453278
[TBL] [Abstract][Full Text] [Related]
29. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
30. Poxvirus cancer therapy.
Gilbert PA; McFadden G
Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):309-21. PubMed ID: 18221156
[TBL] [Abstract][Full Text] [Related]
31. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
32. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.
Nájera JL; Gómez CE; Domingo-Gil E; Gherardi MM; Esteban M
J Virol; 2006 Jun; 80(12):6033-47. PubMed ID: 16731942
[TBL] [Abstract][Full Text] [Related]
33. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
34. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
35. Poxvirus Safety Analysis in the Pregnant Mouse Model, Vaccinia, and Raccoonpox Viruses.
Roper RL
Methods Mol Biol; 2017; 1581():121-129. PubMed ID: 28374246
[TBL] [Abstract][Full Text] [Related]
36. Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.
Kallel H; Kamen AA
Biotechnol J; 2015 May; 10(5):741-7. PubMed ID: 25914340
[TBL] [Abstract][Full Text] [Related]
37. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
38. Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.
Franchini G; Benson J; Gallo R; Paoletti E; Tartaglia J
AIDS Res Hum Retroviruses; 1996 Mar; 12(5):407-8. PubMed ID: 8882320
[No Abstract] [Full Text] [Related]
39. Poxvirus tropism.
McFadden G
Nat Rev Microbiol; 2005 Mar; 3(3):201-13. PubMed ID: 15738948
[TBL] [Abstract][Full Text] [Related]
40. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
